Jaguar Health, Inc.

Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products in pricing, industry trends, and product initiatives, including products in the development stage which may not achieve scientific objectives or meet stringent regulatory requirements. Forelinking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forelinking statements. These statements are based on currently available information and management's current assumptions, expectations, and projections about future events. While management believes its assumptions, expectations, and projections are reasonable in a view of currently available information, you are cautioned not to place undue reliance on these forelinking statements. The company's actual results may differ materially from those discussed during the webcast for a variety of reasons, including those described in the forward-looking statements and risk factors sections of the company's form 10-K for the year 2023, which was filed April 1, 2024, and its other filings with the SEC, which are available on the Investor Relations section of JAGUAR's website. Except as required by law, JAGUAR undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information future events, or otherwise. Additionally, please note that the company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP recurring EBITDA. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which company and management assesses and operates the business. These non-GAAP financial measures should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss, and are not substitutes for or superior to measures of financial performance in conformity with GAAP. Today's conference is being recorded. At this time, it's my pleasure to turn the call over to Lisa Conti, Jaguar Health's founder, president, and chief executive officer. Lisa, the floor is yours.

Three, two, one, here we go. Earnings call for the first quarter of 2024. Hello.

And Peter, just wanted to confirm your line is not on mute. Banzai Miep